Werewolf Therapeutics price target lowered to $4 from $12 at JMP Securities

JMP Securities lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $4 from $12 and keeps an Outperform rating on the shares. Werewolf recently reported 2025 milestone updates, including WTX-124 dose expansion data expected in 4Q25 as well as the initiation of a study targeting WTX-330 to the tumor microenvironment, the analyst tells investors. With multiple data updates expected during 2025, a partnership with Jazz Pharmaceuticals (JAZZ), and a cash position at $122.8M, the firm says Werewolf represents an interesting investment opportunity at current levels.